转移性肾细胞癌患者治疗反应的预测因素：新证据。

Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.

机构信息

Department of Medical Oncology, University Campus Bio-Medico, Via Alvaro del Portillo, 200 00128 Rome, Italy.

出版信息

Expert Rev Anticancer Ther. 2011 Jun;11(6):921-30. doi: 10.1586/era.11.63.

DOI:10.1586/era.11.63

Abstract

Renal cell carcinoma represents approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. Many agents that target angiogenesis (e.g., sunitinib, sorafenib, bevacizumab and pazopanib) and mTOR-targeted therapy (e.g., temsirolimus and everolimus) have been approved as first-line agents. The choice of the most suitable treatment for advanced renal cell carcinoma depends on the definition of risk. In this article, we reviewed the scientific literature identifying predictive factors on the activity/efficacy of a specific therapy.

摘要

肾细胞癌约占成人恶性肿瘤的 3%，是肾脏肿瘤的 90-95%。许多针对血管生成（如舒尼替尼、索拉非尼、贝伐珠单抗和帕唑帕尼）和 mTOR 靶向治疗（如替西罗莫司和依维莫司）的药物已被批准为一线药物。晚期肾细胞癌最合适的治疗方法的选择取决于风险的定义。在本文中，我们回顾了确定特定治疗活性/疗效的预测因素的科学文献。